CD30_淋巴瘤治疗新靶点.pptVIP

Brentuximab vedotin (SGN-35)——毒性 Younes A, et al. J Clin Oncol. 2012; 30(18): 2183-2189 总结 CD30是TNFR家族成员，其生物学效应取决于所表达的细胞系 多种淋巴瘤均有表达，对诊断和预后判断有一定意义 染色技术和结果需要进一步完善和同质化 SGN-35是单抗耦合细胞毒药物的经典案例 CD30靶向治疗在淋巴瘤中具有一定前景 * * * CD30在细胞中的生理功能呈现多样性，所谓多样性是指它既能促进凋亡，又能促进增殖 通过作用于TRAF（也就是TNF受体相关因子），可以激活NF-KB通路，促进细胞凋亡 又可以激活STAT3这条通路以及ERK1，2这条通路来促进细胞生长、恶性转化并抑制凋亡 而具体走那条通路或以哪条通路为主则取决于多种因素：包括肿瘤细胞的种类、细胞外的微环境等因素 * * * * * * * * References : 1. Falini B et al. Blood. 1995;85(1):1-14. 2. International T-Cell Lymphoma Project. J Clin Oncol. 2008;26(25):4124-4130. 3. Swerdlow SH et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC; 2008. 4. Weisenburger DD et al. Blood. 2011;117(12):3402-3408. 5. Savage KJ et al. Blood. 2008;111(12):5496-5504. 6. Stacchini A et al. Am J Clin Pathol. 2007;128(5):854-864. 7. Went P et al. J Clin Oncol. 2006;24(16):2472-2479. 8. Schwartz EJ et al. Am J Clin Pathol. 2008;130(3):343-351. 9. Pongpruttipan T et al. Diagn Pathol. 2011;6(1):79-89. 10. Takeshita M et al. Histopathology. 1995;26(6):539-546. 11. Miyake K et al. Pathol Int. 1994;44(6):428-434. 12. Delsol G et al. In: Swerdlow SH et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC; 2008:312-316. 13. Mason DY et al. In: Swerdlow SH et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC; 2008:317-319. 14. Murray A et al. Am J Pathol. 1995;146(2):509-519. 15. Delabie J et al. Blood. 2011;118(1):148-155. 16. Willemze R et al. Blood. 2005;105(10):3768-3785. 17. Talpur R et al. J Invest Dermatol. 2006;126(3):575-583. 18. Edinger JT et al. Am J Surg Pathol. 2009;33(12):1860-1868. 19. Cerroni L et al. Am J Surg Pathol. 1992;16(6):543-552. 20. El-Shabrawi-Caelen L et al. Arch Dermatol. 2004;140(4):441-447. * * * * * * * * * * * * * * * * * * /oncology Considerations for Optimal Care of Patients With Anaplastic Large-Cell Lymphoma CD30—淋巴瘤治疗的新靶点 内容提要 CD3